Physician profile
Amanda Abbott
NPI 1366997652
$589.88
in general payments reported to CMS, 2019-2025
15 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.36 · 2022: $104 · 2023: $79.18 · 2024: $165 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.35 | 2022-2025 | Vraylar |
| Amgen INC. | $61.34 | 2021-2022 | |
| Axsome Therapeutics, INC. | $56.20 | 2024 | Auvelity |
| Exact Sciences Corporation | $44.53 | 2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $37.06 | 2022 | |
| Cvrx, INC. | $33.53 | 2024 | Barostim Neo System |
| Lilly USA, LLC | $32.58 | 2023-2024 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.42 | 2025 | Caplyta |
| Novo Nordisk INC | $19.29 | 2025 | Wegovy |
| Pacira Pharmaceuticals Incorporated | $18.40 | 2025 | Exparel |
| Sumitomo Pharma America, INC. | $18.07 | 2023 | Myfembree |
| Polynovo North America LLC | $17.82 | 2024 | Novosorb Btm |
| Alkermes, INC. | $15.88 | 2025 | Vivitrol |
| Astrazeneca Pharmaceuticals LP | $12.41 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.